We are live on ! Find out more
CGEM icon

Cullinan Therapeutics

153 hedge funds and large institutions have $654M invested in Cullinan Therapeutics in 2025 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 66 increasing their positions, 41 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

435% more call options, than puts

Call options by funds: $3.88M | Put options by funds: $724K

61% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 18

61% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 41

35% more capital inflows, than outflows

Capital inflows: $119M | Capital outflows: $88M

6% more funds holding

Funds holding: 145 → 153 (+8)

3.57% more ownership

Funds ownership: 103.39% → 106.96% (+3.6%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
153
Holders Change
+8
Holders Change %
+5.52%
% of All Funds
1.84%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
29
Increased
66
Reduced
41
Closed
18
Calls
$3.88​M
Puts
$724​K
Net Calls
+$3.15​M
Net Calls Change
+$3.26​M

CGEM Hedge Fund Activity: Q4 2025 in Review

153 of the 8,319 institutional investors tracked by Wall St. Rank reported a position in Cullinan Therapeutics (CGEM) for Q4 2025, worth a combined $654M — up 80% from $362M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new CGEM positions and 18 closed out — a net gain of 11 holders — while 66 added to existing stakes and 41 trimmed.

The largest buyer was Lynx1 Capital Management, adding an estimated $28.8M. The largest seller was Deerfield Management, cutting an estimated $22.9M.

  • 153 institutional investors held Cullinan Therapeutics (CGEM) as of Q4 2025, up from 145 in Q3 2025.
  • Funds reported $654M of Cullinan Therapeutics stock for Q4 2025, up 80% quarter-over-quarter.
  • 29 funds opened new Cullinan Therapeutics positions in Q4 2025 and 18 closed out, a net change of +11 holders.
  • The largest Cullinan Therapeutics buyer in Q4 2025 was Lynx1 Capital Management, an estimated $28.8M added.
  • The largest Cullinan Therapeutics seller in Q4 2025 was Deerfield Management, an estimated $22.9M sold.

Based on aggregated 13F filings for Q4 2025.